Insmed Incorporated (INSM) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A section indicate positive sentiment overall. Strong financial metrics and optimistic guidance, especially regarding BRINSUPRI and ARIKAYCE, suggest potential stock price growth. The strategic plan highlights multiple upcoming catalysts, including new drug launches and trials. Management's confidence in market access and revenue opportunities further supports a positive outlook. However, some concerns remain about physician prescribing depth and market access clarity. Despite these, the overall tone is optimistic, warranting a positive sentiment rating.
Key Financial Performance
BRINSUPRI Net Revenue (Q4 2025) $144.6 million, representing its first full quarter of launch. The launch exceeded expectations due to strong market adoption and execution.
ARIKAYCE Revenue Growth (2025) 40% growth in Japan compared to 2024, contributing more than 25% of ARIKAYCE's global revenues. Growth attributed to strong commercial execution.
Cost of Product Revenues (Q4 2025) $44.2 million, or 16.8% of revenues. Lower percentage due to positive contributions of BRINSUPRI to the company's gross margin profile.
Cash Position (End of 2025) Approximately $1.4 billion in cash, cash equivalents, and marketable securities. Cash burn included $70 million of one-time items like asset acquisition and milestone payments.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
BRINSUPRI approval and launch: BRINSUPRI was approved and launched in the U.S. in 2025, surpassing expectations with $144.6 million in net revenue in its first full quarter. It targets bronchiectasis and has no competition for several years. The company estimates a peak sales potential of over $5 billion, with potential upside from undiagnosed patients with COPD or asthma.
ARIKAYCE performance: ARIKAYCE showed significant growth, particularly in Japan (40% growth) and Europe. It is expected to expand its addressable market from 30,000 to over 200,000 patients pending Phase III ENCORE trial results.
TPIP development: TPIP received orphan drug designation for pulmonary arterial hypertension (PAH) and is advancing to a single Phase III trial. It is positioned as a potentially differentiated treatment compared to other treprostinil options.
Market expansion for BRINSUPRI: The company is exploring undiagnosed bronchiectasis patients within COPD and asthma populations, potentially expanding the market significantly. Outreach and education programs are being developed to identify these patients.
ARIKAYCE market growth: ARIKAYCE's market is expected to grow significantly with the potential approval of the Phase III ENCORE trial, increasing its addressable market from 30,000 to over 200,000 patients.
Revenue guidance: The company expects BRINSUPRI to generate at least $1 billion in revenue in 2026, with total company revenue doubling compared to 2025.
Cash position: Insmed ended 2025 with $1.4 billion in cash and expects to achieve cash flow positivity without raising additional capital, though it may seek funding for new initiatives.
Pipeline expansion: The company is evaluating new business development opportunities and internal programs to expand its pipeline, including first or best-in-class therapies in respiratory, inflammation, immunology, neurology, and rare diseases.
Focus on BRINSUPRI and ARIKAYCE: The company is prioritizing the U.S. launch of BRINSUPRI and the growth of ARIKAYCE, aiming to maximize their market potential.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Hurdles: The company acknowledges that forward-looking statements inherently involve risks and uncertainties that may cause actual results to differ materially from projections. This includes potential regulatory challenges for new drug approvals and compliance with payer reimbursement requirements.
Market Access and Reimbursement: While over 90% of targeted patient lives have access to BRINSUPRI reimbursement, some payers require documentation such as CT scans and proof of exacerbations, which could create friction in the reimbursement process.
Supply Chain and Operational Costs: The company has made significant investments in the U.S. launch of BRINSUPRI and other programs, which increases operational costs. Additionally, cash burn remains high due to these investments.
Competitive Pressures: Although BRINSUPRI currently has no competition in its disease category, the company acknowledges the potential for future competition and the need to aggressively resource the launch to maintain market leadership.
Economic Uncertainties: The company may need to source additional capital to support new business development and internal programs, which could be impacted by broader economic conditions.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for BRINSUPRI: Revenue guidance for BRINSUPRI is set at at least $1 billion in 2026, driven by strong early performance and favorable market access dynamics.
Total Company Revenue Projection: Total company revenue in 2026 is expected to more than double compared to 2025, supported by BRINSUPRI and ARIKAYCE performance.
BRINSUPRI Peak Sales Estimate: Peak sales for BRINSUPRI are estimated to exceed $5 billion, with potential upside from undiagnosed bronchiectasis patients within COPD and asthma populations.
Expansion of Addressable Market for ARIKAYCE: The Phase III ENCORE trial for ARIKAYCE, expected in March or April 2026, could expand its addressable market from 30,000 to over 200,000 patients.
TPIP Development: TPIP has received orphan drug designation for pulmonary arterial hypertension (PAH) and will enter a Phase III trial in the first half of 2026, with the potential to become the prostanoid of choice for PAH treatment.
Gross-to-Net Guidance for BRINSUPRI: Gross-to-net for BRINSUPRI in 2026 is expected to range from mid-20s to low 30s, consistent with 2025 levels.
Pathway to Profitability: The company expects to achieve cash flow positivity without raising additional capital, though it may seek funding for business development or pipeline expansion.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Do you have any plans to develop other DPP1 inhibitors within respiratory disease to expand your franchise further?
A:Yes, the company intends to bring other DPP1 inhibitors forward, not just in respiratory indications but also in others. For example, 1033 will enter the clinic this year for rheumatoid arthritis and irritable bowel disease. Additionally, other DPP1 inhibitors are being advanced into conditions like COPD and asthma.
Q:Can you provide additional color regarding the guidance for BRINSUPRI, specifically with regards to patient behavior dynamics like compliance, discontinuations, and prescription abandonment?
A:The company has detailed dashboards showing metrics at or above targets, which supports their confidence in achieving at least $1 billion in revenue for BRINSUPRI this year. Metrics such as market access, low discontinuation rates, and reauthorizations are all performing well.
Q:Can you comment on the script trends that SYMPHONY is picking up and how new starts are trending this year?
A:The company does not track SYMPHONY data but describes the launch as very strong. They are confident in achieving $1 billion in revenue by adding quarters 2 through 5 together, based on script trends, physician behavior, and patient surveys.
Q:When will there be more clarity on the refinement of the $1 billion-plus guidance for BRINSUPRI?
A:The company believes it is audacious to provide $1 billion-plus guidance with only one full quarter of data. They emphasize that the market access picture is fantastic and that the guidance reflects confidence in continued acceleration throughout the year.
Q:What is the actual approval rate for BRINSUPRI from start forms to paid drug, and have there been changes in conversion speed?
A:The company is not disclosing specific approval rates but states that they are at or exceeding internal benchmarks. The dashboard metrics indicate a strong position for the launch.
Q:What is the ex-U.S. contribution to the $1 billion-plus guidance for BRINSUPRI in 2026, and what is the launch strategy ex-U.S.?
A:The ex-U.S. contribution to the 2026 guidance is expected to be very small. The strategy includes launching in Europe and Japan, but plans are on hold until clarity on MFN policies is obtained. The contributions will be vastly weighted towards the U.S.
Q:How is the company thinking about additional capital to support business development relative to achieving cash flow positivity?
A:The company sees a clear path to cash flow positivity based on revenue assumptions for BRINSUPRI and ARIKAYCE. Business development is considered incremental and may require accessing markets for capital, but the base business is funded through cash flow positivity.
Q:Why are many physicians writing only one prescription for BRINSUPRI, and what is being done to increase prescribing depth?
A:Physicians often start with one or two patients to assess the drug's safety and efficacy. Positive patient experiences are expected to drive further prescriptions. The company is using a speakers bureau and other programs to educate and encourage prescribing depth.
Q:Have any unknowns related to the BRINSUPRI launch become more known, and will the company continue providing patient starts and prescriber metrics?
A:Unknowns such as market access policies and prescription fulfillment have become clearer, all trending positively. The company will provide additional clarity on revenue guidance but did not confirm if patient starts and prescriber metrics will continue to be shared.
Q:How do you expect pulmonologists to navigate payer requirements around ruling out COPD or asthma as the primary driver of symptoms?
A:Pulmonologists can use CT scans to diagnose bronchiectasis in patients with COPD or asthma who are optimally treated but still exacerbating. The company is educating physicians to consider bronchiectasis in such cases, which could lead to more BRINSUPRI prescriptions.
Q:Is there a correlation between eosinophil levels and the COPD-bronchiectasis overlap, and how does this affect treatment decisions?
A:Physicians follow a treatment paradigm based on the clinical status of COPD or asthma patients. If patients are optimally treated but still exacerbating, physicians may consider bronchiectasis and order a CT scan to confirm the diagnosis.
Q:What is the breakdown of payers requiring documentation versus attestation for BRINSUPRI, and what percentage of covered lives does this represent?
A:The company did not provide a breakdown but stated that benchmarks for documentation requirements are in line or better than expected. The market access picture is described as very strong.
Q:Are most patient reauthorizations for BRINSUPRI expected to occur 6 months after starting therapy, and how seamless is the reauthorization process?
A:Reauthorizations are going well, even for patients changing medical plans. The company has not observed significant friction in the process.
Q:What is the potential revenue opportunity for BRINSUPRI in the 32 million COPD and asthma patients, and what is required to tap into this population?
A:Physicians need to diagnose bronchiectasis in COPD or asthma patients who are still exacerbating despite optimal treatment. This can be done through CT scans. The company is educating physicians to identify such patients, which could significantly expand the BRINSUPRI market.
Q:How critical is it to show a survival benefit in the TPIP IPF study, and will the study design change based on Tyvaso's TETON-1 results?
A:The study design for TPIP IPF is not finalized. The company will consider TETON-1 results and discuss the design with the FDA before finalizing.
Q:Is the $1 billion guidance for BRINSUPRI based solely on patients with 2 or more pulmonary exacerbations?
A:Yes, the guidance is based on patients with 2 or more exacerbations. Additional patients with fewer exacerbations could provide upside.
Q:What is the company's confidence in ARIKAYCE ENCORE data, and what is the bar for approval and commercial success?
A:The company is confident in ARIKAYCE ENCORE data based on previous successful trials. The primary endpoint is culture conversion, and the data is expected to support approval in the U.S. and Japan, significantly expanding the addressable market.
Q:What is the company's strategy to ensure persistence with BRINSUPRI, given potential discontinuation risks?
A:Refills are going well, and the drug's low treatment burden and positive patient experiences are expected to drive persistence. The company is emphasizing the drug's benefits, such as lung function preservation, to encourage continued use.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the approval rate for BRINSUPRI from start forms to paid drug, the breakdown of payers requiring documentation versus attestation, and the percentage of covered lives this represents. Additionally, they did not confirm whether patient starts and prescriber metrics will continue to be shared.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
COPD asthma
III trial
Insmed
PALM PAH
Phase II
Phase III
Today
access dynamic
approval rate
asthma patient
belief
bronchiectasis NTM
bronchiectasis patient
bronchiectasis population
category
conviction
design PALM
documentation
drug designation
exploration
formulation treprostinil
label patient
medicine physician
moment
month launch
opportunity launch
orphan drug
palmitil treatment
patient COPD
patient physician
patient population
peak sale
physician patient
policy
pulmonologists
reimbursement
sale estimate
trial design
INSM Transcript
Insmed Incorporated (INSM) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Neutral3-2
Insmed Incorporated (INSM) Q4 2025 Earnings Call Transcript
Positive2-19
The earnings call summary and Q&A section indicate positive sentiment overall. Strong financial metrics and optimistic guidance, especially regarding BRINSUPRI and ARIKAYCE, suggest potential stock price growth. The strategic plan highlights multiple upcoming catalysts, including new drug launches and trials. Management's confidence in market access and revenue opportunities further supports a positive outlook. However, some concerns remain about physician prescribing depth and market access clarity. Despite these, the overall tone is optimistic, warranting a positive sentiment rating.
Insmed Incorporated (INSM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
Insmed Incorporated (INSM) Presents at Evercore 8th Annual Healthcare Conference Transcript
Neutral12-2
INSM Slides
Insmed Q4 2025 slides reveal strong BRINSUPRI launch, projects 139% revenue growth for 20262026-02-19
Insmed Q3 2025 slides reveal strong BRINSUPRI debut, ARIKAYCE growth accelerates2025-10-30
Insmed Q2 2025 slides reveal 19% revenue growth amid clinical pipeline advances2025-08-07
Insmed Q1 2025 slides: ARIKAYCE sales surge 23% as brensocatib launch approaches2025-05-08
INSM Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
